NASDAQ:CRBU

Caribou Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy CRBU

*Your capital is at risk

$2.00

-0.320 (-13.79%)

At Close: Jun 03, 2026

Caribou Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.35. In total, the insiders bought 9.1M and sold 45.7K CRBU shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	88.35
● Buy	9.1M shares
● Sell	45.7K shares
89% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 25, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 88.35. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 14, 2025 Buy	Common Stock P-Purchase	Haurwitz Rachel E. President And CEO	CEO / President	20 000 Value: $20.4K
Feb 21, 2025 Sell	Common Stock S-Sale	Mcclung Barbara G Chief Legal Officer	Officer	3 564 Value: $5K
Feb 21, 2025 Sell	Common Stock S-Sale	Khan Ruhi Ahmad Chief Business Officer	Officer	3 564 Value: $5K
Feb 21, 2025 Sell	Common Stock S-Sale	Kanner Steven Chief Scientific Officer	Officer	3 564 Value: $5K
Feb 21, 2025 Sell	Common Stock S-Sale	Kanner Steven Chief Scientific Officer	Officer	3 564 Value: $5K
Feb 21, 2025 Sell	Common Stock S-Sale	Khan Ruhi Ahmad Chief Business Officer	Officer	3 564 Value: $5K
Feb 21, 2025 Sell	Common Stock S-Sale	Mcclung Barbara G Chief Legal Officer	Officer	3 564 Value: $5K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Haurwitz Rachel E. President And CEO	CEO / President	618 250 Value: $871.7K
Feb 20, 2025 Buy	Common Stock A-Award	Haurwitz Rachel E. President And CEO	CEO / President	136 750 Value: $192.8K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Albertson Tina M. Chief Medical Officer	Officer	66 137 Value: $93.3K
Feb 20, 2025 Buy	Common Stock A-Award	Albertson Tina M. Chief Medical Officer	Officer	14 589 Value: $20.6K
Feb 20, 2025 Buy	Common Stock A-Award	Mcclung Barbara G Chief Legal Officer	Officer	37 500 Value: $52.9K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Mcclung Barbara G Chief Legal Officer	Officer	170 000 Value: $239.7K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Khan Ruhi Ahmad Chief Business Officer	Officer	170 000 Value: $239.7K
Feb 20, 2025 Buy	Common Stock A-Award	Khan Ruhi Ahmad Chief Business Officer	Officer	37 500 Value: $52.9K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Kelly Timothy P Chief Technology Officer	Officer	170 000 Value: $239.7K
Feb 20, 2025 Buy	Common Stock A-Award	Kelly Timothy P Chief Technology Officer	Officer	37 500 Value: $52.9K
Feb 20, 2025 Buy	Common Stock A-Award	Kanner Steven Chief Scientific Officer	Officer	37 500 Value: $52.9K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Kanner Steven Chief Scientific Officer	Officer	170 000 Value: $239.7K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Zheng Ran Director	Director	40 500 Value: $57.1K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Whiting Nancy Director	Director	40 500 Value: $57.1K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Sacks Natalie Director	Director	40 500 Value: $57.1K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Richardson-heron Dara Director	Director	40 500 Value: $57.1K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Johnson David Lee Director	Director	40 500 Value: $57.1K
Feb 20, 2025 Buy	Option to purchase Common Stock A-Award	Guggenhime Andrew Director	Director	40 500 Value: $57.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CARIBOU BIOSCIENCES, INC.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic ...

Read Full Profile Here